Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation
- PMID: 11090078
Bcl-2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation
Abstract
Growth factor-dependent hematopoietic cell lines expressing the BCR/ABL oncoprotein of the Ph chromosome show growth factor-independent proliferation and resistance to apoptosis. Apoptosis resistance of BCR/ABL-expressing cells may depend on enhanced expression of anti-apoptotic proteins as well as reduced expression and/or inactivation of pro-apoptotic proteins. Compared to myeloid precursor 32Dcl3 cells expressing wild type BCR/ABL, cells expressing a BCR/ABL mutant lacking amino acids 176-426 in the BCR domain (p185 delta BCR) are susceptible to apoptosis induced by interleukin-3 (IL-3) deprivation. These cells exhibited the hypophosphorylated apoptotic BAD and markedly reduced levels of Bcl-2. Upon ectopic expression of Bcl-2, these cells showed no changes in BAD phosphorylation, but they became apoptosis-resistant and proliferated in the absence of IL-3, albeit more slowly than cells expressing wild type BCR/ABL. Moreover, the p185 delta BCR/Bcl-2 double transfectants were leukemogenic when injected into immunodeficient mice, but Bcl-2 expression did not restore the leukemia-inducing effects of p185 delta BCR to the levels of wild type BCR/ABL. Leukemic cells recovered from the spleen of mice injected with p185 delta BCR/Bcl-2 cells did not show rearrangements in the Bcl-2 genomic locus, but they exhibited enhanced proliferation in culture and induced a rapidly fatal disease process when inoculated in secondary recipient mice. Together, these data support the importance of anti-apoptotic pathways for BCR/ABL-dependent leukemogenesis and suggest that Bcl-2 expression promotes secondary changes leading to a more aggressive tumor phenotype. (Blood. 2000;96:3915-3921)
Similar articles
-
Expression of constitutively active Raf-1 in the mitochondria restores antiapoptotic and leukemogenic potential of a transformation-deficient BCR/ABL mutant.J Exp Med. 1998 Jun 15;187(12):1995-2007. doi: 10.1084/jem.187.12.1995. J Exp Med. 1998. PMID: 9625759 Free PMC article.
-
Versatility of BCR/ABL-expressing leukemic cells in circumventing proapoptotic BAD effects.Blood. 2000 Jul 15;96(2):676-84. Blood. 2000. PMID: 10887134
-
BCR/ABL-mediated leukemogenesis requires the activity of the small GTP-binding protein Rac.Proc Natl Acad Sci U S A. 1998 Sep 29;95(20):11858-62. doi: 10.1073/pnas.95.20.11858. Proc Natl Acad Sci U S A. 1998. PMID: 9751755 Free PMC article.
-
The SH3 domain contributes to BCR/ABL-dependent leukemogenesis in vivo: role in adhesion, invasion, and homing.Blood. 1998 Jan 15;91(2):406-18. Blood. 1998. PMID: 9427693
-
Molecular biology of chronic myeloid leukemia.Int J Hematol. 2001 Apr;73(3):308-22. doi: 10.1007/BF02981955. Int J Hematol. 2001. PMID: 11345196 Review.
Cited by
-
_targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary CML stem cells.J Clin Invest. 2009 May;119(5):1109-23. doi: 10.1172/JCI35660. Epub 2009 Apr 13. J Clin Invest. 2009. PMID: 19363292 Free PMC article.
-
Association of promoter polymorphisms of Fas -FasL genes with development of Chronic Myeloid Leukemia.Tumour Biol. 2016 Apr;37(4):5475-84. doi: 10.1007/s13277-015-4295-0. Epub 2015 Nov 13. Tumour Biol. 2016. PMID: 26563376
-
A degradation-resistant c-Myb mutant cooperates with Bcl-2 in enhancing proliferative potential and survival of hematopoietic cells.Blood Cells Mol Dis. 2007 Nov-Dec;39(3):292-6. doi: 10.1016/j.bcmd.2007.06.002. Epub 2007 Jul 23. Blood Cells Mol Dis. 2007. PMID: 17644012 Free PMC article.
-
Bcl-xL anti-apoptotic network is dispensable for development and maintenance of CML but is required for disease progression where it represents a new therapeutic _target.Leukemia. 2013 Oct;27(10):1996-2005. doi: 10.1038/leu.2013.151. Epub 2013 May 14. Leukemia. 2013. PMID: 23670294 Free PMC article.
-
Novel iodoacetamido benzoheterocyclic derivatives with potent antileukemic activity are inhibitors of STAT5 phosphorylation.Eur J Med Chem. 2016 Jan 27;108:39-52. doi: 10.1016/j.ejmech.2015.11.022. Epub 2015 Nov 27. Eur J Med Chem. 2016. PMID: 26629859 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous